Nuvig Therapeutics Inc., a pioneering biopharmaceutical company dedicated to advancing innovative therapies, has announced the successful completion of a $161 million funding round. This substantial investment will accelerate Nuvig's mission to develop transformational treatments aimed at restoring immune homeostasis and rebalancing immune function in patients suffering from chronic inflammatory and autoimmune diseases. The funds will primarily be directed towards the expansion of Nuvig's promising pipeline of novel immune therapeutics, which harness the body’s natural mechanisms to combat various immune-related conditions. With a focus on breakthroughs that improve how patients respond to treatment, Nuvig has positioned itself at the forefront of immunology research, promising to deliver significant advancements in therapeutic options. The funding comes from a consortium of strategic investors who recognize the potential of Nuvig's innovative approach in a domain that desperately requires new therapeutic strategies. As the company gears up for clinical trials, this financial backing will enable the acceleration of research initiatives, bolster operational capabilities, and nurture collaborations with leading research institutions. Ultimately, Nuvig Therapeutics is poised to make a significant impact on the treatment landscape for patients grappling with complex immune disorders, offering hope for better health outcomes and enhanced quality of life. This funding milestone marks a major step forward for Nuvig, allowing them to continue their journey of transforming science into meaningful therapies.
Nuvig Therapeutics Inc. Secures $161 Million in Series B Funding to Advance Groundbreaking Immune Therapies
Recently funded · $161.0M Series bBiotechnology
Get the full Nuvig Therapeutics Inc. company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
